ADMS Adamas Pharmaceuticals, Inc.

17.69
+0  (1%)
Previous Close 17.45
Open 17.45
Price To book 2.91
Market Cap 393.05M
Shares 22,219,000
Volume 128,097
Short Ratio 31.19
Av. Daily Volume 142,023

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102
Multiple sclerosis (MS)
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
PDUFA date August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia

Latest News

  1. Adamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  2. Are These 2 Biotechs Diamonds in the Rough?
  3. Adamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  4. Adamas Announces New Employment Inducement Grant
  5. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : March 10, 2017
  6. ADAMAS PHARMACEUTICALS INC Financials
  7. Adamas to Present at the 37th Annual Cowen Health Care Conference
  8. ADAMAS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
  9. ADAMAS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  10. Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016
  11. 8:32 am Adamas Pharmaceuticals announces the presentation of additional data from EASE LID 2, its Phase 3 open-label, long-term safety and efficacy study of ADS-5102 at the First Pan American Parkinson's Disease and Movement Disorders Congr
  12. Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders Congress
  13. ADAMAS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
  14. Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017
  15. Adamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : January 20, 2017
  16. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : January 19, 2017
  17. Adamas Pharmaceuticals Inc (ADMS) Is Up On PDUFA: What’s Next?
  18. Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%
  19. Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements
  20. Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease